Scope of the SESHAT Project at Pioneering
Hospital, Part of the Catalan Health Institute, Includes Deployment
of up to 1,000 Masimo W1 Watches, 100 Radius VSMs, and Numerous
Additional Masimo Hospital Automation™ Solutions
Masimo (NASDAQ: MASI) today announced that Germans Trias i
Pujol, a pioneering hospital serving more than 800,000 people in
north Barcelona, Spain, is launching a breakthrough telehealth and
remote patient management initiative using Masimo technology. The
SESHAT project is focused on using advanced wearable technologies
and wireless connectivity to allow remote clinicians to keep track
of patients’ physiological data in near real time wherever they
are, whether the patient is in another part of the hospital or at
home. The project, which began in the fourth quarter of 2023 and is
slated to last at least three years, includes the implementation of
up to 1,000 Masimo W1® medical watches, 100 Radius VSM™ Wearable
Continuous Vital Signs Monitors, 10 Patient SafetyNet™ Systems, and
a host of additional Masimo Hospital Automation™ products.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240602519106/en/
Masimo W1®, Radius VSM™, Root®, Patient
SafetyNet™, and UniView® (Photo: Business Wire)
Joe Kiani, Founder and CEO of Masimo, said, “We are honored to
partner with Germans Trias i Pujol to support the SESHAT project.
When I founded Masimo 35 years ago, our mission was to improve
patient outcomes and reduce the cost of care by taking noninvasive
monitoring to new sites and applications. Now, with decades of
innovation and refinement, we are bringing our pioneering accurate
and continuous monitoring technologies to even more new sites and
applications, including the home – with powerful wearable,
tetherless, and remote modalities like Masimo SET®-based Masimo W1
and Radius VSM. Our breakthrough predictive algorithm Halo™,
AI-powered tools, and connectivity and automation solutions in turn
make that accurate, precise, rich stream of actionable patient data
available to clinicians when and where they need it, helping
patients feel connected and cared for, and informing evermore
insightful decisions about care. Ultimately, we believe this will
improve outcomes while reducing the cost of care, in keeping with
our founding mission. We look forward to gleaning innumerable
insights and improving 800,000 lives with the forward-thinking
clinicians of Germans Trias i Pujol.”
Dr. Oriol Estrada, Director of Healthcare Strategy and
Innovation at Germans Trias, commented, “Project SESHAT, named for
the Egyptian goddess of writing and measurement, aims to transform
healthcare from a reactive to a predictive model thanks to
continuous and real-time reliable patient data measured through
wearable technology, both in hospital and at home.”
The SESHAT project arose from needs identified during the COVID
pandemic and centers on the remote monitoring of patients with
complex care requirements. The project's goal is to obtain
real-time physiological data from patients and have that data help
clinicians improve health outcomes. By facilitating better tracking
of each patient’s physiological changes, and combining such changes
with other available health data, SESHAT project clinicians hope to
design and validate better prospective indicators of clinical
progress and therapeutic adherence. Their goal is ultimately to
help institutions transition from a reactive care model, in which
healthcare teams treat symptomatic diseases, to a more proactive
model in which teams receive information that enables them to
anticipate complications or select more suitable medications to
ensure a better therapeutic response, based on each patient's
profile.
“To achieve these objectives,” continued Dr. Estrada, “wearable
technology that is robust, reliable, and does not hinder the
patient's normal life had to be selected. After analyzing various
options, Masimo technology embedded in medical-grade wearable
devices such as Masimo W1 and Radius VSM was chosen. A decisive
factor in this choice was Masimo's willingness to become a
technological partner beyond just being a technology provider. We
have established a strategic collaboration whereby the SESHAT
project will serve as a validation field for technological
improvements and identification of new needs in which both
institutions will cooperate. When deciding, it was important for
the project leaders to work with a leading company in the
monitoring technology sector that offers a portfolio with a global
solution for all phases of patient care: from the hospital to the
home, while also providing integration with Hospital Information
Systems.”
The Germans Trias i Pujol University Hospital of Badalona
belongs to the Catalan Health Institute. It is a high-tech center
that provides health services to a population of 800,000
inhabitants in the North Metropolitan area of Barcelona. Since its
foundation, the hospital has been a pioneer in the development and
care in various areas of excellence, such as infectious,
cardiovascular, inflammatory, oncological, and respiratory
diseases, among others. It encompasses a powerful biomedical
research campus with 12 internationally renowned institutions,
employing over 6,000 professionals and researchers in the field of
health. Clinical innovation—transforming clinical problems into
opportunities for improving outcomes—is one of the institution's
strategic pillars.
Halo is not FDA cleared and is not available in the U.S.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.1
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,2 improve CCHD screening in
newborns3 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.4-7 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,8 and is
the primary pulse oximetry at 9 of the top 10 hospitals as ranked
in the 2022-23 U.S. News and World Report Best Hospitals Honor
Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7®,
Radius PPG®, and Radius VSM™, portable devices like Rad-67®,
fingertip pulse oximeters like MightySat® Rx, and devices available
for use both in the hospital and at home, such as Rad-97® and the
Masimo W1® medical watch. Masimo hospital and home automation and
connectivity solutions are centered around the Masimo Hospital
Automation™ platform, and include Iris® Gateway, iSirona™, Patient
SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo
SafetyNet®. Its growing portfolio of health and wellness solutions
includes Radius Tº®, Masimo W1 Sport, and Masimo Stork™. Additional
information about Masimo and its products may be found at
www.masimo.com. Published clinical studies on Masimo products can
be found at www.masimo.com/evidence/featured-studies/feature/.
RPVi has not received FDA 510(k) clearance and is not available
for sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo W1™, Radius VSM™,
Hospital Automation™, SET®, the partnership of Masimo and Germans
Trias i Pujol Hospital (the “Partnership”), and the prospect of
SESHAT project. These forward-looking statements are based on
current expectations about future events affecting us and are
subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo W1, Radius VSM, Hospital Automation,
and SET®, as well as the Partnership and the SESHAT project
,contribute to positive clinical outcomes and patient safety; risks
related to our belief that Masimo noninvasive medical breakthroughs
provide cost-effective solutions and unique advantages; risks
related to the assumption that the SESHAT project will last at
least three years; risks related to COVID-19; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether
our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240602519106/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From May 2024 to Jun 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Jun 2023 to Jun 2024